Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023


Cosmo Pharmaceuticals N.V. / Key word(s): Annual Results
Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023

16.03.2023 / 06:00 GMT/BST


Dublin, Ireland – 16 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its full-year 2022 results on Thursday, 23 March 2023 at 07:00 am CET.

 

Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast which will follow at 2:00 pm CET with Mauro Ajani, Founder and Chairman, Alessandro Della Chà, CEO, and Niall Donnelly, CFO, to discuss the 2022 financial and operating results as well as the next milestones of the company.

 

Live conference call and video webcast presentation:

Date:  Thursday, 23 March 2023
Time:  2:00 pm CET

Webcast link: Chrome (recommended) or Firefox https://media.choruscall.eu/mediaframe/webcast.html?webcastid=L3HNXtf4


Please note that there is a function to type in your questions via webcast.

Via phone:

Participants wishing to ask verbal questions via phone, may call the following numbers below. To ensure prompt access, please call approximately ten minutes prior to the scheduled start of the call.

Switzerland / Europe

+41 (0) 58 310 50 00

United Kingdom

+44 (0) 207 107 06 13

United States

+1 (1) 631 570 56 13

 

The presentation and media release as well as the Annual Report 2022 will be available for download as of 07:00 am CET on 23 March 2023 at www.cosmopharma.com


Replay

The webcast, along with the presentation, will be available online shortly after the event and accessible for three months.

 

 

Contact:

Hazel Winchester

Head of Investor Relations

Cosmo Pharmaceuticals N.V.

Tel: +353 1 817 03 70

[email protected]



End of Media Release


Language: English
Company: Cosmo Pharmaceuticals N.V.
Riverside 2, Sir John Rogerson’s
Dublin 2 Dublin
Ireland
Phone: + 353 1 817 0370
E-mail: [email protected]
Internet: https://www.cosmopharma.com/
ISIN: NL0011832936
Listed: SIX Swiss Exchange
EQS News ID: 1583775

 
End of News EQS News Service

1583775  16.03.2023 GMT/BST

fncls.ssp?fn=show_t_gif&application_id=1583775&application_name=news&site_id=sharewise

Cosmo Pharmaceuticals S.A. Stock

€72.50
-0.680%
Cosmo Pharmaceuticals S.A. shows a slight decrease today, losing €0.000 (-0.680%) compared to yesterday.

Like: 0
Share
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments